A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1
Phase of Trial: Phase I/II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs ALN GO1 (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions; First in man
- Sponsors Alnylam Pharmaceuticals
- 20 Jul 2017 Planned number of patients changed from 60 to 64.
- 20 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Jan 2020.
- 20 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History